Over 6 million people in the US are living with Alzheimer disease (AD)1, and over 80 million adults between 50-70 years whose biggest health fear, other than cancer, is AD2.
We want to help them all.
Our ATN Profile is based on years of research on individual markers that, together, reflect the biological changes consistent with Alzheimer’s disease.
Each of the biomarker tests are orderable individually.
Labcorp is working hard, combining the power of new high precision technology with artificial intelligence to advance diagnostic testing in order to provide clear, objective answers to clinicians, patients, and families.
We are working with blood-based biomarkers, like pTau and NfL, and collaborating with pharmaceutical and diagnostic partners to develop tests that identify, diagnose and monitor patients with AD.